High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin'... ( Novel Outpatient Regimen Pioneered by...)

HOME >> BIOLOGY >> TECHNOLOGY

High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma

Date:10/19/2008

Novel Outpatient Regimen Pioneered by Investigators from Tumor Institute in

Milan

SEATTLE, Oct. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Journal of Clinical Oncology has published the results of an innovative study that investigated high (bone marrow ablative) dose Zevalin(R) ([90Y]-ibritumomab tiuxetan) followed by autologous stem cell infusions among 30 patients (median age 62 years) with relapsed/refractory or high risk aggressive non-Hodgkin's lymphoma (NHL) not eligible for a chemotherapy-based transplant. High-dose myeloablative chemotherapy is an effective therapy for NHL but because it is associated with significant toxicities it is usually reserved for clinically fit and younger patients and therefore is not an option for many due to the average age of NHL patients being approximately 60 years old. In this study, three cycles of conventional chemotherapy were given followed by high dose chemotherapy with a stem cell rescue and then followed by up to three times the standard dose of Zevalin with an additional stem cell rescue. This treatment regimen resulted in 83 percent of patients achieving a disease free state with a projected overall survival of 87 percent after a median follow up of 30 months.

"Our results suggest that the use of high-dose Zevalin for these patients provides a significant clinical benefit and is very well tolerated," said Alessandro M. Gianni, M.D., Full Professor of Medical Oncology and Director of the School of Specialization in Medical Oncology at the University of Milan. "We are encouraged by the outcome of the study as this regimen could be applicable to the vast majority of high risk or relapsed non-Hodgkin's lymphoma patients."

High-dose Zevalin was well tolerated and no deaths were noted with this regimen. The expected severe marrow suppression associated with myeloablative treatment was seen but patien
'/>"/>

3

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
2. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
3. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
4. CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
5. Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkins Lymphoma
6. Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkins Lymphoma
7. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
8. FDA Meeting Provides Green Light for Cell Therapeutics Submission of Supplemental Filing for Zevalin(R) Label Expansion
9. Tandem Labs New England Facility Doubles Discovery Support Capacity - Increasing Foothold in New England
10. DW Healthcare Partners Announces the Sale of Tandem Labs
11. CardiacAssist, Inc. Surpasses 1300 TandemHeart System Procedures

Post Your Comments:

High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin'...( Novel Outpatient Regimen Pioneered by...)